Английская Википедия:Insulin icodec
Шаблон:Short description Шаблон:Use dmy dates Шаблон:Cs1 config Шаблон:Infobox drug
Insulin icodec is an investigational ultralong-acting basal insulin analogue that is developed by Novo Nordisk.
It has a plasma half-life more than eight days[1] (compared to 25 hours of the previous longest-acting insulin analogue insulin degludec), making it a once-weekly basal insulin.[1]
Like insulin, icodec is composed of two peptide chains linked by a disulfide bridge. However, a C20 fatty diacid-containing side chain has been added for strong, reversible albumin binding; and three amino acid substitutions provide molecular stability and attenuate insulin receptor binding and clearance. Together, these modifications prolong the half-life.[2]
Insulin icodec is the international nonproprietary name.[3]
Society and culture
Legal status
In March 2024, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Awiqli, intended for the treatment of diabetes.[4] The applicant for this medicinal product is Novo Nordisk A/S.[4]
Research
Based on a clinical trial, glycemic control was found to be non-inferior with once-weekly insulin icodec compared with once-daily insulin glargine U100.[5]
References
Шаблон:Oral hypoglycemics and insulin analogs Шаблон:Portal bar Шаблон:Authority control
- ↑ 1,0 1,1 Шаблон:Cite journal
- ↑ Шаблон:Cite journal
- ↑ Шаблон:Cite journal
- ↑ 4,0 4,1 Шаблон:Cite web Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ↑ Шаблон:Cite journal